6.
Tabata R, Tabata C, Uesugi H, Takei Y
. Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate. Int Immunopharmacol. 2019; 68:213-217.
DOI: 10.1016/j.intimp.2019.01.014.
View
7.
Momose S, Tamaru J
. Iatrogenic immunodeficiency-associated lymphoproliferative disorders of B-cell type that develop in patients receiving immunosuppressive drugs other than in the post-transplant setting. J Clin Exp Hematop. 2019; 59(2):48-55.
PMC: 6661961.
DOI: 10.3960/jslrt.19014.
View
8.
Bibas M, Castillo J
. Current knowledge on HIV-associated Plasmablastic Lymphoma. Mediterr J Hematol Infect Dis. 2014; 6(1):e2014064.
PMC: 4235470.
DOI: 10.4084/MJHID.2014.064.
View
9.
Li Y, Li J, Chen K, Li J, Zhong M, Liu X
. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. Blood Res. 2020; 55(1):49-56.
PMC: 7106118.
DOI: 10.5045/br.2020.55.1.49.
View
10.
Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D
. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013; 91(1):20-8.
DOI: 10.1111/ejh.12116.
View
11.
Kaur S, Kollimuttathuillam S
. Plasmablastic Lymphoma: Past, Present, and Future. Clin Lymphoma Myeloma Leuk. 2023; 23(9):e253-e259.
DOI: 10.1016/j.clml.2023.05.014.
View
12.
Castillo J, Bibas M, Miranda R
. The biology and treatment of plasmablastic lymphoma. Blood. 2015; 125(15):2323-30.
DOI: 10.1182/blood-2014-10-567479.
View
13.
Di Ciaccio P, Polizzotto M, Cwynarski K, Gerrie A, Burton C, Bower M
. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood. 2023; 143(2):152-165.
DOI: 10.1182/blood.2023021348.
View
14.
Vega F, Chang C, Medeiros L, Udden M, Cho-Vega J, Lau C
. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2004; 18(6):806-15.
DOI: 10.1038/modpathol.3800355.
View
15.
Saito R, Tanaka M, Ito H, Kuramoto N, Fujii T, Saito S
. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study. Mod Rheumatol. 2020; 32(1):50-58.
DOI: 10.1080/14397595.2020.1866837.
View
16.
Omameuda T, Miyato H, Sata N, Lefor A
. Primary hepatic methotrexate-associated lymphoproliferative disorder associated with Epstein-Barr virus reactivation and accompanied by spontaneous necrosis: A case report. Medicine (Baltimore). 2022; 101(47):e31993.
PMC: 9705001.
DOI: 10.1097/MD.0000000000031993.
View
17.
Bailly J, Jenkins N, Chetty D, Mohamed Z, Verburgh E, Opie J
. Plasmablastic lymphoma: An update. Int J Lab Hematol. 2022; 44 Suppl 1:54-63.
PMC: 9545967.
DOI: 10.1111/ijlh.13863.
View
18.
Coppo P, Ricard L
. Plasmablastic lymphoma: better refine prognosis. Blood. 2024; 143(2):101-102.
DOI: 10.1182/blood.2023022639.
View
19.
Castillo J, Winer E, Stachurski D, Perez K, Jabbour M, Milani C
. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011; 11(2):185-9.
DOI: 10.1016/j.clml.2011.03.008.
View